Destiny Pharma plc Stock price

Equities

DEST

GB00BDHSP575

Biotechnology & Medical Research

Market Closed - London S.E. 12:35:22 2024-03-28 pm EDT 5-day change 1st Jan Change
25.5 GBX -7.27% Intraday chart for Destiny Pharma plc -15.00% -63.57%
Sales 2023 * 977K 1.23M Sales 2024 * 533K 673K Capitalization 26.21M 33.08M
Net income 2023 * -5M -6.31M Net income 2024 * -5M -6.31M EV / Sales 2023 * 19.6 x
Net cash position 2023 * 7.07M 8.93M Net cash position 2024 * 2.04M 2.57M EV / Sales 2024 * 45.3 x
P/E ratio 2023 *
-4.11 x
P/E ratio 2024 *
-4.65 x
Employees 24
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day-8.57%
1 week-16.19%
Current month-22.63%
1 month-21.42%
3 months-64.33%
6 months-50.70%
Current year-64.08%
More quotes
1 week
24.50
Extreme 24.5
32.60
1 month
24.50
Extreme 24.5
35.75
Current year
24.50
Extreme 24.5
80.00
1 year
24.50
Extreme 24.5
84.00
3 years
24.50
Extreme 24.5
250.00
5 years
24.50
Extreme 24.5
250.00
10 years
24.50
Extreme 24.5
250.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 23-08-31
Founder 62 96-03-03
Director of Finance/CFO 56 18-10-23
Members of the board TitleAgeSince
Chairman 76 11-08-31
Founder 62 96-03-03
Director/Board Member - 22-05-31
More insiders
Date Price Change Volume
24-03-28 25.5 -7.27% 455 375
24-03-27 27.5 +1.85% 221,888
24-03-26 27 -12.90% 605,942
24-03-25 31 0.00% 150,356
24-03-22 31 +3.33% 111,207

Delayed Quote London S.E., March 28, 2024 at 08:06 am EDT

More quotes
Destiny Pharma plc is a clinical-stage biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines with a focus on infection prevention. Its pipeline includes microbiome-based biotherapeutics and XF drug clinical assets, which includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. Its lead drug candidate, NTCD-M3, is in Phase III ready treatment for the prevention of Clostridioides difficile infection (CDI) recurrence, which causes hospital acquired infection in the United States. Its second lead candidate, XF-73 nasal gel, which has completed Phase IIb clinical trial targeting the prevention of post-surgical staphylococcal hospital infections, including methicillin-resistant Staphylococcus aureus (MRSA). The Company is also co-developing SPOR-COV, a biotherapeutic product for the prevention of COVID-19 and influenza, an in-house XF-73 dermal program, targeting wound and skin infections, and other XF research projects.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.275 GBP
Average target price
2.083 GBP
Spread / Average Target
+657.57%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Destiny Pharma plc - London S.E.